Objective: To review clinical data on the use of long-acting bronchodilator agents as
monotherapy and in combination for the treatment of moderate-to-severe chronic obstructive …

Chronic obstructive pulmonary disease (COPD) accounts for a major workload in both
primary and secondary care. It is characterised by progressive airflow obstruction which …

BACKGROUND:: Tiotropium bromide is a new inhaled anticholinergic agent approved for
once-daily, long-term maintenance treatment of bronchospasm associated with chronic …

Bronchodilators play an important role in the treatment of chronic obstructive pulmonary
disease (COPD) and anticholinergics have a long history as an effective and safe treatment …

Background: In chronic obstructive pulmonary disease (COPD), inhaled tiotropium bromide,
a long-acting anticholinergic, has been shown to exert a sustained bronchodilator effect and …

OBJECTIVE To evaluate and compare the cost-effectiveness of long-acting bronchodilators
by estimating incremental costs per quality-adjusted life-year (QALY) gained in patients with …

OBJECTIVE: To review the scientific literature evaluating the efficacy and tolerability of
tiotropium bromide, a new bronchodilator indicated for treatment of chronic obstructive …

Chronic obstructive pulmonary disease (COPD), a respiratory disease characterized by a
progressive decline in lung function, is considered to be a leading cause of morbidity and …

Tiotropium is a potent, long-acting, selective anticholinergic bronchodilator. Treatment with
tiotropium produces sustained improvements in lung function, particularly FEV1 (peak …

Bronchodilator therapy forms the mainstay of treatment for symptomatic patients with COPD.
Long-acting bronchodilators, which maintain sustained airway patency over a 24-hour …